S/N: 10/586,542 Page 2 of 8

612-455-3801

RECEIVED CENTRAL FAX CENTER DEC 0 4 2009

## AMENDMENT TO THE CLAIMS

Please amend the claims in the following Listing of Claims which shall replace any previous listing. No new matter has been added.

## Listing of Claims

1. (Currently Amended) A process for purification of optically impure Ramipril to obtain Ramipril(I) having the chemical formula (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-aminolpropanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid of formula (1)

having optical purity of at least 99.9 %, which comprises crystallizing optically impure Ramipril from an organic solvent selected from nitromethane, dimethoxymethane, diethoxymethane, and 2,2, -dimethoxy propane and mixtures thereof.

- 2. (Previously Presented) The process as claimed in claim 1 wherein the organic solvent is diethoxymethane.
- 3. (Withdrawn) A monohydrate of Ramipril(I), characterized by the following X-ray powder diffraction pattern

S/N: 10/586,542 Page 3 of 8

612-455-3801

| Diffraction angle | Relative Intensity |
|-------------------|--------------------|
| <u>2 θ</u>        | (%)                |
| 8.7               | 16                 |
| 9.2               | 3                  |
| 9.4               | 3                  |
| 9.7               | 3                  |
| 11.2              | 81                 |
| 11.6              | 33                 |
| 12,2              | 66                 |
| 14.54             | 96                 |
| 15.7              | 70                 |
| 18.0              | 51                 |
| 19.7              | 81                 |
| 24.5              | 49                 |
| 24.8              | 30                 |

4. (Withdrawn) The Ramipril(I) monohydrate as claimed in claim 3 having an X-ray diffractogram, or substantially the same X-ray diffractogram, as set out in Figure 1a.

S/N: 10/586,542 Page 4 of 8

04/12/2009 11:36

- 5. (Withdrawn) The Ramipril(I) monohydrate as claimed in claim 3 having DSC thermogram as described in Fig. 1c.
- (Withdrawn) The Ramipril(I) monohydrate as claimed in claim 3 having TGA thermogram as described in Fig. 1d.
- (Withdrawn) A process for preparation of Ramipril(I) monohydrate comprising of crystallizing optically impure Ramipril from a mixture of water and water-immiscible solvents.
- 8. (Withdrawn) The process claimed in claim 7 wherein the ratio of water-immiscible solvent to water is in the range from 2 to 98% w/w.
- 9. (Withdrawn) The process as claimed in claim 8 wherein the said water-immiscible solvent is selected from an aliphatic ester, an acetal, a hydrocarbon or a mixture thereof.
- 10. (Withdrawn) The process as claimed in claim 8 wherein the said water-immiscible solvent is selected from diisopropyl ether, diethoxymethane, 2,2-dimethoxy propane, cyclohexane, methyl isobutyl ketone and ethyl acetate or a mixture thereof.
- 11. (Withdrawn) A process for preparation of Ramipril(I) monohydrate comprising of crystallizing optically pure Ramipril(I) from water.
- 12. (Withdrawn) A pharmaceutical composition comprising an effective ACE inhibitory amount of Ramipril(I) monohydrate as claimed in , together with one or more pharmaceutically acceptable carriers, diluents or excipients thereof.

04/12/2009 11:36

S/N: 10/586,542 Page 5 of 8

13. (New) The process as claimed in claim 1, wherein the optically pure Ramipril(1) is obtained by the process consisting essentially of the crystallizing from the organic solvent.